Drugs & Targets BMS, Infinity form collaboration to evaluate Opdivo + IPI-549 in urothelial cancer November 09, 2018Vol.44 No.42
Drugs & Targets ASCO, SITC release recommendations for reporting of immuno-oncology clinical trials November 09, 2018Vol.44 No.42
Drugs & Targets FDA’s digital tool seeks to help capture real world data useful in regulatory decision-making November 09, 2018Vol.44 No.42
Drugs & Targets Elsevier to integrate NCCN guidelines into Via Oncology November 09, 2018Vol.44 No.42
Drugs & TargetsFree FDA approves Keytruda + carboplatin and either paclitaxel or nab-paclitaxel for first-line metastatic squamous NSCLC November 02, 2018Vol.44 No.41
Drugs & TargetsFree FDA accepts sNDA for Lonsurf for metastatic gastric/gastroesophageal junction adenocarcinoma; grants Priority Review November 02, 2018Vol.44 No.41
Drugs & TargetsFree Venclexta + Gazyva reduced risk of disease worsening or death in previously untreated CLL with co-morbidities November 02, 2018Vol.44 No.41
Drugs & TargetsFree TESARO achieves Zejula prostate cancer development milestone by Janssen November 02, 2018Vol.44 No.41
Drugs & TargetsFree Cofactor Genomics launches ImmunoPrism kit for use in clinical sequencing laboratories November 02, 2018Vol.44 No.41
